Skip to Content

Optimizing the front-line PARP-inhibitor treatment of ovarian cancer from a Nordic perspective

How can we use tests to optimise ovarian cancer treatment with PARP-inhibitor? In this MEDtalk, Kristina Yvonne Kathe Lindemann, Associate Professor – Department of Gynaecological Oncology, Oslo University Hospital, gives her perspective on how we can secure which patients benefit from the treatment.

Kristina Lindemann

Get access

If you are a doctor, nurse, or other health professionals, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top